Cryptococcal meningitis post autologous stem cell transplantation

S Chaaban1, L J Wheat, M Assi

  • 1Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.

Insights

This case highlights early Cryptococcus meningitis in a stem cell transplant (SCT) patient despite fluconazole prophylaxis. Prompt diagnosis and treatment are crucial for survival in these high-risk opportunistic infections.

Area of Science:

  • Infectious Diseases
  • Hematology
  • Oncology

Background:

  • Disseminated Cryptococcus disease typically affects individuals with compromised T-cell immunity.
  • Cryptococcal meningitis post-autologous stem cell transplant (SCT) is rare, with only one prior reported case occurring months after transplant and without antifungal prophylaxis.

Observation:

  • A 41-year-old man with non-Hodgkin's lymphoma developed fever and headache on day 9 post-autologous SCT, while on fluconazole prophylaxis.
  • Brain MRI revealed meningoencephalitis, and cerebrospinal fluid (CSF) analysis confirmed Cryptococcus neoformans meningitis with a positive cryptococcal antigen and culture.
  • The patient presented with a low white blood cell count (700/μL) and signs of central nervous system infection.

Findings:

  • This is the first reported case of Cryptococcus meningitis occurring pre-engraftment after autologous SCT despite continuous fluconazole prophylaxis.
  • Literature review identified 9 cases of cryptococcal disease in SCT recipients, with a median onset of 64 days post-transplant; only 3 were meningitis cases, 2 post-allogeneic SCT.
  • The patient successfully responded to treatment with liposomal amphotericin B and flucytosine, followed by fluconazole, achieving CSF sterilization.

Implications:

  • This case underscores the need for a high index of suspicion for opportunistic infections like Cryptococcus meningitis in immunosuppressed patients, even with adequate prophylaxis.
  • Early diagnosis and prompt initiation of appropriate antifungal therapy, such as amphotericin B, are critical for improving outcomes and potentially saving lives in SCT recipients.
  • Current recommendations for fungal prophylaxis with fluconazole post-autologous SCT should be considered, especially through engraftment and potentially longer for high-risk individuals.